Suppression of the immune system as a critical step for bone formation from allogeneic osteoprogenitors implanted in rats

被引:23
作者
Chatterjea, Anindita [1 ]
LaPointe, Vanessa L. S. [1 ]
Alblas, Jacqueline [2 ]
Chatterjea, Supriyo [3 ]
van Blitterswijk, Clemens A. [1 ]
de Boer, Jan [1 ]
机构
[1] Univ Twente, Dept Tissue Regenerat, MIRA Inst Biomed Technol & Tech Med, NL-7500 AE Enschede, Netherlands
[2] Univ Med Ctr Utrecht, Dept Orthopaed, Utrecht, Netherlands
[3] Univ Twente, Pervas Syst Grp, NL-7500 AE Enschede, Netherlands
关键词
Mesenchymal stromal cells; bone tissue engineering; allogeneic cells; immunology; immunosuppression; MARROW STROMAL CELLS; IN-VIVO; POROUS HYDROXYAPATITE; TISSUE; IMMUNOGENICITY; CERAMICS; TRANSPLANTATION; EXPRESSION; PHENOTYPE; INJECTION;
D O I
10.1111/jcmm.12172
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The surface marker profile of mesenchymal stromal cells (MSCs) suggests that they can escape detection by the immune system of an allogeneic host. This could be an optimal strategy for bone regeneration applications, where off-the-shelf cells could be implanted to heal bone defects. However, it is unknown how pre-differentiation of MSCs to an osteogenic lineage, a means of improving bone formation, affects their immunogenicity. Using immunohistological techniques in a rat ectopic implantation model, we demonstrate that allogeneic osteoprogenitors mount a T cell- and B cell-mediated immune response resulting in an absence of in vivo bone formation. Suppression of the host immune response with daily administration of an immunosuppressant, FK506, is effective in preventing the immune attack on the allogeneic osteoprogenitors. In the immunosuppressed environment, the allogeneic osteoprogenitors are capable of generating bone in amounts similar to those of syngeneic cells. However, using osteoprogenitors from one of the allogeneic donors led to newly deposited bone that was attacked by the host immune system, despite the continued administration of the immunosuppressant. This suggests that, although using an immunosuppressant can potentially suppress the immune attack on the allogeneic cells, optimizing the dose of the immunosuppressant may be crucial to ensure bone formation within the allogeneic environment. Overall, allografts comprising osteoprogenitors derived from allogeneic MSCs have the potential to be used in bone regeneration applications.
引用
收藏
页码:134 / 142
页数:9
相关论文
共 33 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics [J].
Akahane, M ;
Ohgushi, H ;
Yoshikawa, T ;
Sempuku, T ;
Tamai, S ;
Tabata, S ;
Dohi, Y .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (04) :561-568
[3]  
Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
[4]   Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect [J].
Arinzeh, TL ;
Peter, SJ ;
Archambault, MP ;
van den Bos, C ;
Gordon, S ;
Kraus, K ;
Smith, A ;
Kadiyala, S .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2003, 85A (10) :1927-1935
[5]   Mesenchymal stromal cells for tissue-engineered tissue and organ replacements [J].
Baiguera, Silvia ;
Jungebluth, Philipp ;
Mazzanti, Benedetta ;
Macchiarini, Paolo .
TRANSPLANT INTERNATIONAL, 2012, 25 (04) :369-382
[6]   Mesenchymal stem cell effects on T-cell effector pathways [J].
Duffy, Michelle M. ;
Ritter, Thomas ;
Ceredig, Rhodri ;
Griffin, Matthew D. .
STEM CELL RESEARCH & THERAPY, 2011, 2
[7]   Allogeneic Mesenchymal Stem Cells: Agents of Immune Modulation [J].
English, Karen ;
Mahon, Bernard P. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (08) :1963-1968
[8]   Comparing various off-the-shelf methods for bone tissue engineering in a large-animal ectopic implantation model: Bone marrow, allogeneic bone marrow stromal cells, and platelet gel [J].
Geuze, Ruth E. ;
Kruyt, Moyo C. ;
Verbout, Abraham J. ;
Alblas, Jacqueline ;
Dhert, Wouter J. A. .
TISSUE ENGINEERING PART A, 2008, 14 (08) :1435-1443
[9]  
Geuze RE, 2009, TISSUE ENG PT A, V15, P3231, DOI [10.1089/ten.tea.2009.0023, 10.1089/ten.TEA.2009.0023]
[10]   The mechanism of action of cyclosporin A and FK506 [J].
Ho, S ;
Clipstone, N ;
Timmermann, L ;
Northrop, J ;
Graef, I ;
Fiorentino, D ;
Nourse, J ;
Crabtree, GR .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 80 (03) :S40-S45